Overview

* Sera Prognostics Q3 2025 revenue was $16,000

* Net loss for Q3 2025 was $7.8 mln, slightly improved from last year

* Company progresses on Medicaid pilot in Nevada, engaging with multiple payers

Outlook

* Company is advancing discussions with Medicaid plans covering 33% of U.S. births

* Company aims to secure broad coverage at employer, plan, and state levels

Result Drivers

* Research and development expenses for the third quarter of 2025 were $3.3 million, compared to $3.5 million for the third quarter of 2024

Key Details

Metric Beat/Mis Actual Consensu

s s

Estimate

Q3 Miss $16,000

Revenue

Q3 Net -$7.81

Income mln

Q3 Basic -$0.16

EPS

Q3 -$8.98

Income mln

from

Operatio

ns

Q3 $9 mln

Operatin

g

Expenses

Analyst Coverage

* The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

* The average consensus recommendation for the business support services peer group is "buy."

Press Release:

For questions concerning the data in this report, contact [email protected]. For any other questions or feedback, contact .

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)